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Enterotoxigenic Escherichia coli (ETEC) is a common cause of bacterial infection leading to
acute watery diarrhea in infants and young children as well as in travellers to ETEC endemic
countries. Ciprofloxacin is a broad-spectrum antimicrobial agent nowadays used for the
treatment of diarrhea. This study aimed to characterize ciprofloxacin resistant ETEC strains
isolated from diarrheal patients in Bangladesh.
Methods
A total of 8580 stool specimens from diarrheal patients attending the icddr,b Dhaka hospital
was screened for ETEC between 2005 and 2009. PCR and Ganglioside GM1- Enzyme
Linked Immuno sorbent Assay (ELISA) was used for detection of Heat labile (LT) and Heat
stable (ST) toxins of ETEC. Antimicrobial susceptibilities for commonly used antibiotics and
the minimum inhibitory concentration (MIC) of nalidixic acid, ciprofloxacin and azithromycin
were examined. DNA sequencing of representative ciprofloxacin resistant strains was per-
formed to analyze mutations of the quinolone resistance-determining region of gyrA, gyrB,
parC and parE. PCR was used for the detection of qnr, a plasmid mediated ciprofloxacin
resistance gene. Clonal variations among ciprofloxacin resistant (CipR) and ciprofloxacin
susceptible (CipS) strains were determined by Pulsed-field gel electrophoresis (PFGE).
Results
Among 1067 (12%) ETEC isolates identified, 42% produced LT/ST, 28% ST and 30% LT
alone. Forty nine percent (n = 523) of the ETEC strains expressed one or more of the 13
tested colonization factors (CFs) as determined by dot blot immunoassay. Antibiotic resis-
tance of the ETEC strains was observed as follows: ampicillin 66%, azithromycin 27%,
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ciprofloxacin 27%, ceftriazone 13%, cotrimaxazole 46%, doxycycline 44%, erythromycin
96%, nalidixic acid 83%, norfloxacin 27%, streptomycin 48% and tetracycline 42%. Resis-
tance to ciprofloxacin increased from 13% in 2005 to 34% in 2009. None of the strains was
resistant to mecillinam. The MIC of the nalidixic acid and ciprofloxacin of representative
CipR strains were 256 μg/ml and 32μg/ml respectively. A single mutation (Ser83-Leu) in
gyrA was observed in the nalidixic acid resistant ETEC strains. In contrast, double mutation
in gyrA (Ser83-Leu, Asp87-Asn) and a single mutation in parC (Glu84-Ly) were found in cipro-
floxacin resistant strains. Mutation of gyrB was not found in either the nalidixic acid or cipro-
floxacin resistant strains. None of the ciprofloxacin resistant strains was found to be positive
for the qnr gene. Diverse clones were identified from all ciprofloxacin resistant strains by
PFGE analysis in both CF positive and CF negative ETEC strains.
Conclusion
Emergence of ciprofloxacin resistant ETEC strains results in a major challenge in current
treatment strategies of ETEC diarrhea.
Introduction
Enterotoxigenic E. coli (ETEC) is the most important cause of diarrhea among children under
5 years of age in developing countries and among travellers in ETEC endemic countries [1, 2].
ETEC express one or both of two types of enterotoxins, namely heat stable (ST) and/or heat
labile (LT) toxin which are encoded by the same or separate plasmids [3–5], and may produce
one or more of several colonization factors (CFs) [6, 7]. In case of human challenge studies
where ETEC strains were used [8], ampicillin was the only antibiotic used for the treatment
and clearing of bacteria. When ETEC strains were first isolated in Calcutta in 1968, no antimi-
crobial resistance was reported. Additionally, a completely uniform sensitivity pattern was also
observed in ETEC strains isolated from Apache children in Arizona during 1971 [9]. Studying
the effects of antimicrobial treatment in children with ETEC disease has been difficult for two
reasons. Firstly, childhood diarrhea is caused by ETEC as well as other bacterial and viral
agents. Secondly, the clinical presentations are not sufficient to differentiate among the various
pathogenic organisms responsible for diarrhea. One retrospective study of ETEC diarrhea in
Bangladeshi patients has shown that in adults, only a minimal effect on the severity of diarrhea
was evident when tetracycline was used for treatment [10].
Antimicrobial treatment of traveller’s diarrhea, which is caused by ETEC in about 20–50%
of cases, has altered over the years due to increasing antimicrobial resistance [11]. The rise in
multidrug resistance in organisms, such as ETEC, can be attributed to the widespread and
indiscriminate use of chemotherapeutic agents in countries where diarrhea is endemic. Hence,
it has become imperative to use newer antimicrobials for treating traveller’s diarrhea. The anti-
biotics that have been used so far are ciprofloxacin, doxycycline, sulfamethoxazole-trimetho-
prim, erythromycin, norfloxacin, ofloxacin, azithromycin and rifamycin [12–14].
Fluoroquinolones are powerful broad-spectrum antimicrobial agents for the treatment of a
wide variety of community acquired and nosocomial infections [15]. However, resistance to
fluoroquinolones has increased markedly since their introduction in the late 1980s [16].
Recently ciprofloxacin resistance Shigella and Salmonella has emerged lately in Bangladesh
[17, 18]. In 2001 ciprofloxacin resistant ETEC was isolated from patients in India [19]. A recent
study conducted in 2008–2009 demonstrated the presence of ciprofloxacin resistant ETEC in
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the drinking water of Bangladesh [20]. No studies have yet been carried out on fluoroquino-
lones resistance mechanism of ETEC in Bangladesh.
Several studies showed that fluoroquinolones mainly target DNA gyrase, a type II DNA
topoisomerase, in gram-negative organisms [21]. DNA gyrase is composed of two subunits,
namely A (gyrA) and B (gyrB). Although the subunit A is highly conserved within bacterial
species, most of the mutations reported so far in DNA gyrase are within this subunit [21].
Alterations in subunit A have been documented in a variety of species, including E. coli, Shi-
gella, Salmonella, and Campylobacter [22, 23]. On the contrary, mutations in subunit B, which
is associated with quinolone resistance, have been rarely isolated in clinical samples [24]. In
addition to targeting DNA gyrase, fluoroquinolones also target topoisomerase IV. Toposiomer-
ase IV is also composed of two subunits, namely parC and parE, which share significant
sequence similarity to the subunits A and B of DNA gyrase [25].
The aim of the present study was to compare the antimicrobial resistance pattern, clonal
variation, and sequence analysis of Quinolone resistance-determinig regions (QRDR) of gyrA,
gyrB, parC and parE mutations in ciprofloxacin resistant ETEC strains.
Material and Methods
Ethics statement
The International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b) carries out a
Surveillance of diarrheal patients attending the Dhaka Hospital where every fiftieth patient’s
stool specimens were screened for enteric pathogens [26]. Informed oral consent is obtained
from the caregivers or guardians on behalf of the patients for collecting specimens. The 2% sur-
veillance is approved by the Institutional Review Board (IRB) of icddrb. The patients or the
guardians are assured about the non-disclosure of information collected from them, but are
also informed about the use of data for analysis and keeping identity of the participants
anonymous.
Collection and culture of clinical specimens
A total number of 8580 stool specimens were collected from patients, both male (59%) and
female (41%), with diarrhea identified from 2% systematic surveillance system [27] at the
icddr,b hospital at Dhaka between 2005 and 2009. Two percentage systematic surveillance
system means every 50th patient irrespective of age, sex, disease severity or socioeconomic
status by administering structured questionnaire. The generated data provides valuable
information to hospital clinicians in their decision- making processes and enables the detec-
tion of emerging pathogens and early identification of outbreaks and their locations as well
as antimicrobial susceptibility pattern. All stool samples were inoculated onto MacConkey
agar, Taurocholate-tellurite-gelatin agar and Salmonella–Shigella agar plates (Difco, Becton
Dickinson & Company, Sparks, MD, USA). ETEC, Vibrio cholerae, Shigellae and Salmonel-
lae were isolated and identified by using standard microbiological and biochemical methods
[28]. Shigella and Salmonella species were confirmed using commercial antisera kits (Denka
Seiken, Tokyo, Japan). Vibrio cholerae were confirmed using a combination of biochemical
and serological methods as described previously [29, 30]. For the detection of ETEC, fresh
stool specimens were inoculated onto MacConkey agar and the plates were incubated for
18h at 37°C. Six lactose fermenting individual colonies morphologically resembling E.coli
from MacConkey agar plates were tested immediately for the presence of toxins and CFs as
described below.
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Detection of toxin types and CFs
The detection of LT and ST was carried out by multiplex PCR and ganglioside GM1 enzyme-
linked immunosorbent assays (ELISA) [31, 32]. The colonies tested for toxin production were
also cultured on Colonization factor antigen (CFA) agar plates with and without bile salts [7,
33]. Enterotoxin positive E. coli colonies from CFA agar plates were tested for the expression of
CFA/I, CS1, CS2, CS3, CS4 and CS6 and colonies from CFA agar plus bile plates were tested
for the expression of CS5, CS7, CS8, CS12, CS14 and CS17 by monoclonal antibody-based dot
blot assays [31, 34]. Strains grown on TSA were tested for CS21 only [35].
Antimicrobial susceptibility
Antimicrobial agents from Oxoid, Basingstoke, United Kingdom were used to determine bacte-
rial susceptibility by using the guidelines of National Committee for Clinical Laboratory Stan-
dards [36]. The antibiotic discs used in the study included ampicillin (10 μg), azithromycin
(15 μg), ceftriaxone (30 μg), ciprofloxacin (5 μg), doxycycline (30 μg), erythromycin (15 μg),
mecillinam (25 μg), nalidixic acid (30 μg), norfloxacin (10 μg), streptomycin (10 μg), sulfo-
methoxazole-trimethoprim (25 μg) and tetracycline (30 μg). The minimum inhibitory concen-
trations (MIC) of nalidixic acid, ciprofloxacin, and azithromycin were determined by the E-test
(AB Biodisk, Solna, Sweden) according to the NCCL guideline. E. coli ATCC 25922, susceptible
to all antimicrobials was used as a control strain for susceptibility studies. We performed anti-
biogram of all ETEC strains collected during the study period and randomly selected the repre-
sentative nalidixic acid and ciprofloxacin resistant strains. These strains were compared with a
few representative nalidixic and ciprofloxacin susceptible strains for genotyping.
Pulsed-field gel electrophoresis (PFGE)
Intact chromosomal DNA of clinical ETEC strains was prepared and digested with the XbaI
restriction endonuclease (New England Biolabs) according to the PulseNet program descried
elsewhere [37]. DNA fragments were separated by pulsed-field gel electrophoresis on a CHEF--
MAPPER apparatus (Bio-Rad) under the following conditions: switching time from 2.2 to 54.2
s at 6 V cm−1 for 20 h at 14°C. Analysis of the TIFF image was carried out by the BioNumerics
software version 4.5 (Applied Maths, Belgium) with average linkages to generate dendrogram
at 1.5% tolerance level using the dice coefficient and unweighted-pair group method.
PCR and sequencing amplification of gyrA, gyrB, parC and parE
Chromosomal DNA was prepared and purified by procedures described earlier [38]. Polymer-
ase chain reaction (PCR) for gyrA, gyrB, parC and parE were done according to the methods
described earlier [39–41].
Nucleotide sequencing. GFX PCR DNA and gel band purification kit (Amersham Phar-
macia, USA) were used for the purification of gyrA, gyrB, parC and parE PCR amplicons.
Sequencing of the purified PCR products were performed by using the dideoxynucleotide
chain termination method with an ABI PRISM BigDye Terminator Cycle Sequencing Reaction
kit (Perkin-Elmer Applied Biosystems, Foster City, CA, USA) on an automated sequencer
(ABI PRISM 310) at the icddr,b core sequencing facility.
DNA and protein sequence analysis. The chromatogram sequencing files were inspected
using Chromas 2.23 (Technelysium, Queensland, Australia), and contiguous sequences were
prepared using SeqMan II (DNASTAR, Madison, WI, USA). Nucleotide and protein sequences
were analyzed using the National Center for Biotechnology Information (NCBI, National Insti-
tutes of Health, Bethesda, MD, USA) BLAST (Basic Local Alignment Search Tool) server on
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GenBank database, release 138, in order to find similarities with previously known sequences
[42] Multiple sequence alignments developed using CLUSTALX 1.81 [43] sequences were
manually edited in the Gene Doc version 2.6.002 alignment editor.
Results
Isolation of enteric pathogens from stool specimens
A total of 8580 stool specimens were tested from patients at the icddr,b hospital during the
period between 2005–2009 for the isolation of Vibrio cholerae, ETEC, Shigella, and Salmonella.
Of 8580 specimens, a total of 3194 pathogens were isolated, of them 21% (1784/8580) were V.
cholerae O1, 12% (1067/8580) were ETEC, 3.0% (259/8580) were Shigella spp. and rest 1.0%
(84/8580) was Salmonella spp. Of V. cholerae O1, 74% were Ogawa and 26% were Inaba
serotypes.
Toxin types and CFs on ETEC
Among the ETEC isolates, 448 (42%) were both LT and ST followed by the strains producing
LT alone 315 (30%) and ST only 304 (28%) (Table 1). In the present study 523 (49%) of the
ETEC strains expressed one or more CFs; CFA/I, CS5+CS6 and CS7 were the predominant
phenotypes during the study period.
Antibiotic resistance pattern
The majority of the ETEC strains isolated during the study period showed high resistance
(Table 2) to the 12 different antibiotics tested, including members of the quinolone (nalidixic
acid) and fluoroquinolone groups (ciprofloxacin or norfloxacin). Antibiotic resistance pattern
was as follows: ampicillin 66%, azithromycin 27%, ciprofloxacin 27%, ceftriazone 13%, sulfo-
methoxazole-trimethoprim 46%, doxycycline 44%, erythromycin 96%, nalidixic acid 83%, nor-
floxacin 27%, streptomycin 48% and tetracycline 42% respectively. Resistance to ciprofloxacin
increased from 13% in 2005 to 34% in 2009. However none of the strains was resistant to
mecillinam.
Most of the fluoroquinolone resistant ETEC strains tested were CF negative 84% (n = 204).
All ETEC strains were tested for 13 colonization factors using 13 specific monoclonal antibod-
ies. A probable reason for the above results may be that other colonization factors were not
tested. Moreover, ETEC strains might have possibly lost the plasmids harboring the CF genetic
elements because of repeated subculture in vitro or a mutation in genetic locus. Multiple antibi-
otic resistance patterns and the minimum inhibitory concentrations (MIC) of the representa-
tive ciprofloxacin resistant strains are shown in (Table 3). The range of MIC values of the
ciprofloxacin was 32 μg/ml and nalidixic acid 64–256 μg/ml.
Table 1. Number of ETEC strains isolated during the study period and their toxin types.
Year No. of specimens tested ETEC No. (%) ETEC toxin Types
LT ST LT+ST
2005 654 91(14) 24 (26) 42 (46) 25 (28)
2006 661 82 (12) 27 (33) 21 (26) 34 (41)
2007 2211 291 (13) 100 (34) 70 (24) 121 (42)
2008 2369 319 (13) 89 (28) 87 (27) 143 (45)
2009 2685 284 (11) 75 (26) 84 (30) 125 (44)
Total (2005–2009) 8580 1067 (12) 315 (30) 304 (28) 448 (42)
doi:10.1371/journal.pone.0157415.t001
Ciprofloxacin Resistant ETEC in Bangladesh
PLOS ONE | DOI:10.1371/journal.pone.0157415 July 18, 2016 5 / 11
Identification of mutations and clonal variations
Further investigation using gene-sequencing QRDR (Quinolone resistance-determining
region) of gyrA, gyrB, parC and parE was performed to investigate the mutations of nalidixic
acid and ciprofloxacin resistant ETEC strains. A single mutation (Ser83-Leu) in gyrA was
observed in the nalidixic acid resistant ETEC strains. In contrast, double mutation in gyrA
(Ser83-Leu, Asp87-Asn)) and a single mutation in parC (Glu84-Ly) was found in all of the most
recently isolated fluoroquinolone resistant strains in diarrheal patients. Mutation of gyrB was
not found either in nalidixic acid or ciprofloxacin resistant strains. No mutation in gyrA, gyrB,
parC and parE was observed by gene sequence analyses among the quinolone and fluoroquino-
lone susceptible ETEC strains.
PFGE typing of representative ciprofloxacin resistant strains (n = 12) of different ETEC
toxin types (LT, LT/ST and ST ETEC) showed that more than one clone was detected within a
specific toxin type (Fig 1).
Discussion
Analyses of data from patients hospitalized in diarrheal hospitals, have shown that patients
with ETEC diarrhea are often given antibiotic treatment together with rehydration therapy
[44]. The treatment is similar to that given to patients with V. cholerae induced diarrhea. This
is done to reduce duration of hospital stay as well as decrease of transmission of diarrheal path-
ogens in the environment. However, careful monitoring of antimicrobial sensitivity in treated
patients is generally not carried out. Our results show that ETEC is also following a similar
Table 2. Resistant pattern of ETEC strains isolated during the study periods (2005–2009).
Name of antibiotics 2005* (N = 91) (%) 2006* (N = 82) (%) 2007* (N = 277) (%) 2008* (N = 191) (%) 2009* (N = 262) (%)
Ampicillin (A) 53 60 66 70 71
Azithromycin (Azm) 5 13 22 32 33
Ciproﬂoxacin (Cip) 13 26 25 26 34
Ceftriaxone (Cro) 4 6 13 13 17
Doxycline (D) 33 35 46 49 44
Erythromycin (E) 95 95 96 97 100
Nalidixic Acid (Na) 70 76 80 90 87
Norﬂoxacin (Nor) 13 26 25 26 34
Streptomycin (S) 35 39 51 47 53
Sulfomethoxazole-trimethoprim (Sxt) 38 49 49 51 41
Tetracycline (T) 31 32 43 49 44
* Number of ETEC strains tested during the year
doi:10.1371/journal.pone.0157415.t002
Table 3. MIC values and amino acids changes in gyrA and ParC in representative ETEC strains isolated in Bangladesh.
Strain Toxin types CFs Resistance pattern MIC (μg/ml) Substitution in QRDRc
Na Cip Azm gyrA ParC
2533700 LT+ST CS5+CS6 Sensitive 2 0.012 0.38 - - - - - -
2960200 LT+ST CS1+CS3+CS21 Sensitive 0.008 1 0.75 - - - - - -
2511850 ST CFA/I E Na Sxt T 256 0.19 1 Ser83 Leu - - - -
2526600 LT Negative A Cip D E Na Sxt T 256 32 4 Ser83 Leu Asp87 Asn Glu84 Ly
2848150 LT Negative A Azm Cip D E Na Sxt T 256 32 256 Ser83 Leu Asp87 Asn Glu84 Ly
0008200 ST Negative A Azm Cip Cro D E Na S Sxt T 256 32 256 Ser83 Leu Asp87 Asn Glu84 Ly
doi:10.1371/journal.pone.0157415.t003
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trend of increased antibiotic resistance to drugs commonly used for treatment of V. cholerae
O1 and other diarrheal infections [45, 46].
Our present analysis showed that 88% of ETEC strains isolated from stools of diarrheal
patients attended at a 2% surveillance system at icddr,b Dhaka Hospital in Bangladesh during
five years (2005–2009) were multidrug resistant. Resistance was observed to nalidixic acid and
ciprofloxacin as well as reduced sensitivity to azithromycin and ceftriaxone. There have been
reports from India and Japan on multidrug resistance to the fluoroquinolones in ETEC strains
isolated during outbreaks [19, 46]. In this study no CFs were detected in 84% of the ciprofloxa-
cin resistant strains. Similar finding was also observed in India [19]. A recent study, reported
the presence of ciprofloxacin resistant ETEC in environmental samples during 2008–2009 in
Bangladesh [20]. This change is trend in Bangladesh is alarming as these antibiotics are used
for the treatment of enteric infections.
Quinolones are broad-spectrum antibacterial agents that act by inhibiting the DNA gyrase
and topoisomerase IV activities [47]. We showed that the isolated ciprofloxacin resistant ETEC
strains on sequencing had a single mutation in gyrA gene in the nalidixic acid resistant strains
and double mutation in gyrA in the ciprofloxacin resistant ETEC strains. In addition, a single
mutation in parC was found in fluoroquinolone resistant ETEC strains. This suggests that gyrA
and parC are intracellular targets of quinolones and fluoroquinolones, and that mutation in
these genes are associated with fluoroquinolones and/or quinolones resistance in E. coli, which
is also supported by previous studies [40, 48]. No mutation in gyrB was observed in the
Fig 1. BioNumeric software generated dendrogram. The distances shownwere calculated by the dice similarity index of
PFGE XbaI profiles for clinical ETEC isolates isolated from Bangladesh. The scale shows the degree of similarity (%).
doi:10.1371/journal.pone.0157415.g001
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ciprofloxacin and nalidixic acid resistant ETEC strains examined in our study. Among the
quinolone and fluoroquinolone-susceptible ETEC strains, however, no mutations were
observed in gyrA, gyrB, parC and parE by sequence analysis. PCR analysis also showed that
none of the strains was found to carry the qnr gene. The qnr gene encodes an immune protein
which protects E. coli gyrase from quinolone inhibition. Hence, along with these factors, addi-
tional factors may also be involved in mediating fluoroquinolone resistance in ETEC. Although
in vitro drug resistance pattern not always be related to in vivo activity of the drug, it may indi-
cate the trend of the sensitivity. Our results show that ETEC strains with fluoroquinolone resis-
tance is increasing in Bangladesh and also that the gyrA and parC genes were mutated. There
are important informations for therapeutic purposes. However it may mention that in vitro
drug resistance pattern has not always been found to correlate with in vivo activity and indicate
treatment successor.
Dendogram analysis of representative ETEC strains indicated that Ciprofloxacin resistance
in ETEC was not clonally related, since Cip resistance due to gyrA gene mutation was acquired
by diverse clones of ETEC. Thus, similar to earlier observations, we did not find any relation-
ship with the toxin phenotype, CFs or antibiotic resistance pattern [6] among the ciprofloxacin
resistant strains.
In summary, multidrug resistance pattern of ETEC strains especially to fluroquinoles is a
matter of great concern for appropriate management of ETEC diarrhea. This also underscores
the need for the dissemination of this information not only for control of endemic ETEC diar-
rheal diseases but also for traveler’s diarrhea. Thus immunoprophylaxis guarantee with effec-
tive vaccines is required to prevent ETEC diarrheal cases globally.
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